Status and phase
Conditions
Treatments
About
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
Full description
To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
Are willing/able to follow instructions from the study investigator and his/her study staff.
Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
50 participants in 1 patient group
Loading...
Central trial contact
Erika Julca, LPN,CRC; Jayesh Kanuga, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal